Trial ID 20326 | Maryland Oncology Hematology Trial ID 20326 – Maryland Oncology Hematology

Trial ID 20326

Trial Information - Phase III

OVELIA: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

Disease Specifics: HER2- premenopausal

Protocol ID: TOL2506A

Sponsor: Tolmar, Inc

Status: PENDING OPEN

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724

Disease Types

Breast

Investigator

Tweed MD, Carol

Status

PENDING OPEN

Sponsor

Tolmar, Inc

Quality Care Close to Home


View our locations on map!

Sign Up Today For Our E-Newsletter

  • This field is for validation purposes and should be left unchanged.
United in Healing with The US Oncology Network - Maryland Oncology Hematology